Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.55 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20208539 | 0.84 | SCN5A (0.60) | SCN5ACYP1A2DYRK1AFYN | |
| SCHEMBL20208536 | 0.84 | SCN5A (0.60) | SCN5ACYP1A2DYRK1AFYN | |
| SCHEMBL937201 | 0.78 | CYP1A2 (1.00) | SCN5ACYP1A2DYRK1ASCN1ASCN2A | |
| SCHEMBL20208558 | 0.76 | SCN5A (0.71) | SCN5ACYP1A2FYNMAPTSCN1A | |
| SCHEMBL20209202 | 0.76 | SCN5A (0.64) | SCN5ACYP1A2DYRK1AMAPTSCN1A | |
| SCHEMBL937481 | 0.75 | CYP1A2 (0.75) | SCN5ACYP1A2DYRK1AMAPTSCN1A | |
| SCHEMBL20208545 | 0.75 | SCN5A (1.00) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL20203774 | 0.73 | CYP1A2 (0.80) | SCN5ACYP1A2DYRK1ASCN1ASCN2A | |
| SCHEMBL20208512 | 0.72 | DYRK1A (0.59) | SCN5ACYP1A2DYRK1AMAPTSCN1A | |
| SCHEMBL937513 | 0.72 | CYP1A2 (0.70) | SCN5ACYP1A2DYRK1ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885DYRK1A 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.